Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s price objective would indicate a potential upside of 362.96% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Price Performance

HOTH stock opened at $1.08 on Tuesday. The firm has a market cap of $7.45 million, a price-to-earnings ratio of -0.82 and a beta of 0.80. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The firm has a fifty day moving average price of $1.14 and a two-hundred day moving average price of $0.94.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.01). As a group, analysts expect that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.